MedTrace Logo

A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection

NCT06966284 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 480

Last updated 2026-03-09

No results posted yet for this study

Summary

This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with carbapenem-resistant gram-negative bacterial infection. Subgroup analysis by sites of infection, infectious pathogens, and baseline renal function will also be performed.

Conditions

  • Bacteremia Caused by Gram-Negative Bacteria
  • Bacterial Pneumonia

Sponsors & Collaborators

  • TTY Biopharm

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-26
Primary Completion
2028-11-30
Completion
2028-11-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06966284 on ClinicalTrials.gov